Kventiax

Quetiapine, the active ingredient in Kventiax, is a atypical antipsychotic presented as a oral tablet for oral use. It treats schizophrenia, bipolar disorder (both manic and depressive phases) and is used as adjunctive therapy for major depressive disorder in adults.

GNH USA supplies Kventiax as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine is used in the treatment of several psychiatric disorders by modulating dopamine and serotonin pathways. - Schizophrenia: reduces hallucinations, delusions and other psychotic symptoms. - Bipolar disorder (manic episodes): stabilises mood and diminishes mania severity. - Bipolar disorder (depressive episodes): alleviates depressive symptoms when used alone or with other agents. - Major depressive disorder (adjunctive): enhances response to primary antidepressants in patients with insufficient improvement.

Quetiapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: feeling of sleepiness or fatigue. - Dry mouth: reduced salivation leading to discomfort. - Constipation: infrequent bowel movements or hard stools. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Orthostatic hypotension: sudden drop in blood pressure causing dizziness or fainting.

When prescribing quetiapine, clinicians should consider several safety and handling precautions. - Cardiovascular monitoring: assess blood pressure and heart rate regularly. - Metabolic screening: check glucose, lipid profile, and weight periodically. - CNS depression: avoid operating machinery or driving if drowsiness occurs. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Drug discontinuation: taper dose gradually to reduce withdrawal or relapse risk. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Quetiapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels, raising toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower quetiapine concentrations, reducing effectiveness. - Antihypertensives: enhanced orthostatic hypotension. - Anticholinergic agents: may worsen dry mouth and constipation.